Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Regulatory News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.85
Bid: 3.80
Ask: 3.90
Change: 0.00 (0.00%)
Spread: 0.10 (2.632%)
Open: 3.85
High: 3.85
Low: 3.85
Prev. Close: 3.85
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of General Meeting & Total Voting Rights

15 May 2020 10:47

RNS Number : 0666N
Fusion Antibodies PLC
15 May 2020
 

 

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Result of General Meeting

Total Voting Rights

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that all resolutions put to shareholders at the Company's General Meeting held earlier today have been passed. As a result, the 1,124,214 Second Placing Shares being issued pursuant to the Placing announced on 28 April 2020 are expected to be admitted to trading on AIM on 20 May 2020 ("Admission") to complete the Placing. Voting at the general meeting was conducted by way of a poll. The Company will publish the detailed voting results on its website, www.fusionantibodies.com, later today.

 

Total Voting Rights

On Admission, the Company will have 25,424,525 ordinary shares of 4p each in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of ordinary shares and voting rights is 25,424,525.

 

The above figure of 25,424,525 may be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Defined terms used in this announcement shall have the same meaning as in the announcement of 28 April 2020 unless otherwise defined herein.

 

Enquiries:

 

Fusion Antibodies plc

www.fusionantibodies.com

 

Dr Paul Kerr, Chief Executive Officer

Via Walbrook PR

 

James Fair, Chief Financial Officer

 

 

 

 

 

Allenby Capital Limited

Tel: +44 (0)20 3328 5656 

 

James Reeve / Asha Chotai

 

 

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com

 

Anna Dunphy

Mob: +44 (0)7876 741 001

 

Paul McManus

Mob: +44 (0)7980 541 893

 

 

 

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 100 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotechs get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. 

 

The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMFIFSAEEIELII
Date   Source Headline
11th Mar 20243:04 pmRNSHolding(s) in Company
11th Mar 20249:10 amRNSHolding(s) in Company
8th Mar 20243:09 pmRNSHolding(s) in Company
5th Mar 202410:40 amRNSResult of General Meeting and Total Voting Rights
29th Feb 20245:00 pmRNSTotal Voting Rights
27th Feb 20247:00 amRNSFirst purchase order under MSA
14th Feb 20247:15 amRNSGrant of options and issue of shares to directors
14th Feb 20247:00 amRNSPlacing to raise £1,375,000
6th Feb 20247:00 amRNSFollow-on project award and R&D update
1st Feb 20247:00 amRNSHMRC R&D tax credit
4th Dec 202312:26 pmRNSDirector/PDMR Shareholding
4th Dec 20237:00 amRNSHalf-year Report
28th Nov 20237:00 amRNSOptiMAL collaboration agreement
9th Nov 20237:00 amRNSHalf year trading update
27th Oct 202311:57 amRNSResult of AGM
4th Oct 20232:45 pmRNSBlock admission six monthly return
29th Sep 20237:00 amRNSFinal Results
29th Aug 20237:00 amRNSUpdate on AI/ML-Ab service offering
24th Aug 20237:00 amRNSAppointment of interim CFO
21st Aug 20237:00 amRNSUpdate on AI/ML-Ab™ antibody discovery service
14th Aug 20237:00 amRNSUpdate on restructure and cost savings
30th Jun 20235:00 pmRNSTotal Voting Rights
16th Jun 202310:09 amRNSHolding(s) in Company
15th Jun 20239:45 amRNSHolding(s) in Company
13th Jun 20232:44 pmRNSHolding(s) in Company
12th Jun 20233:34 pmRNSHolding(s) in Company
12th Jun 202311:02 amRNSDirector/PDMR Shareholding
8th Jun 202310:39 amRNSResult of GM and total voting rights
31st May 20235:00 pmRNSTotal Voting Rights
26th May 20234:57 pmRNSHolding(s) in Company
26th May 20231:33 pmRNSHolding(s) in Company
23rd May 20237:00 amRNSResult of Retail Offer and Notice of GM
19th May 202310:01 amRNSREX Retail Offer
19th May 202310:00 amRNSPlacing, Subscription and Retail Offer
3rd Apr 20237:00 amRNSBlock listing Interim Review
31st Mar 20237:00 amRNSChange of Registered Office
21st Mar 20237:00 amRNSPatent application
6th Mar 202311:05 amRNSSecond Price Monitoring Extn
6th Mar 202311:00 amRNSPrice Monitoring Extension
6th Mar 20237:00 amRNSTrading Statement
9th Feb 20237:00 amRNSR&D update: Mammalian Display service
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20232:05 pmRNSSecond Price Monitoring Extn
9th Jan 20232:00 pmRNSPrice Monitoring Extension
9th Jan 202311:05 amRNSSecond Price Monitoring Extn
9th Jan 202311:00 amRNSPrice Monitoring Extension
5th Dec 20227:00 amRNSHalf-year Report
24th Nov 20227:00 amRNSNotice of Results
31st Oct 20221:47 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.